



TEMPORARY ADMINISTRATIVE ORDER
INCLUDING STATEMENT OF NEED & JUSTIFICATION
BP 9-2025
CHAPTER 855
BOARD OF PHARMACY

FILED
08/29/2025 2:33 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Temporarily suspending the current version of the Standard Vaccination Protocols temporary rule

EFFECTIVE DATE: 08/29/2025 THROUGH 02/08/2026

AGENCY APPROVED DATE: 08/29/2025

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

NEED FOR THE RULE(S):

Temporarily suspends the current protocol versions for standard vaccine protocols to align with the most current Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations.

JUSTIFICATION OF TEMPORARY FILING:

Failure to suspend this Temporary rule may result in compromised patient access and care, posing a significant risk to public health by leaving individuals vulnerable to preventable diseases and potentially overwhelming other healthcare providers.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

ACIP Recommendations: <https://www.cdc.gov/acip/vaccine-recommendations/index.html>

SUSPEND: 855-115-0345

SUSPEND: Temporary 855-115-0345 from BP 8-2025

RULE TITLE: Services: Prescribing Pursuant to - Protocol

RULE SUMMARY: This Temporary rule is being suspended.

RULE TEXT:

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at <https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>.

(1) Continuation of therapy Protocol including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024)

(2) Conditions Protocols:

(a) Cough and cold symptom management

(A) Benzonatate (v. 06/2021);

- (B) Short-acting beta agonists (v. 06/2021);
- (C) Intranasal corticosteroids (v. 06/2021);
- (b) COVID-19 Antigen Self-Test (v. 12/2021);
- (c) SARS-CoV-2 Antiviral (v. 08/2024)
- (3) Preventative Care Protocols:
 - (a) Emergency Contraception (v. 06/2021);
 - (b) Male and female condoms (v. 06/2021);
 - (c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);
 - (d) Travel Medications (v. 06/2024);
 - (e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);
 - (f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023);
 - (g) Contraception (v. 06/2025);
 - (h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);
 - (i) Short-acting Opioid Antagonists (v. 06/2024); and
- (4) Vaccine Protocols:
 - (a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 08/13/2025);
 - (b) Vaccination Protocol for Ages 7 through 17 Years (v. 08/13/2025);
 - (c) Vaccination Protocol for Ages 3 through 6 Years (v. 08/13/2025);
 - (d) Vaccination Protocol for Ages 6 months through 2 Years (v. 08/13/2025); and
 - (e) Vaccination Protocol for Managing Adverse Reactions (v. 08/2025).

[Publications: Publications referenced are available from the agency.]

STATUTORY/OTHER AUTHORITY: ORS 689.205, ORS 689.005

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005